Tyrosine kinase inhibitors in treatment of fibrous histiocytoma

Aim: To describe potential beneficial effects of tyrosine kinase inhibitor in the treatment of unresectable/metastatic fibrous histiocytoma. Methods: We report a case of advanced stage fibrous histiocytoma with locally recurrent disease plus lung and bone metastatic deposits. Patient was treated w...

Повний опис

Збережено в:
Бібліографічні деталі
Опубліковано в: :Experimental Oncology
Дата:2009
Автори: Maur, D., Panou, C., Valachis, A., Kamposioras, K., Tsali, L.
Формат: Стаття
Мова:English
Опубліковано: Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України 2009
Теми:
Онлайн доступ:https://nasplib.isofts.kiev.ua/handle/123456789/135111
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
Назва журналу:Digital Library of Periodicals of National Academy of Sciences of Ukraine
Цитувати:Tyrosine kinase inhibitors in treatment of fibrous histiocytoma / D. Mauri, C. Panou, A. Valachis, K. Kamposioras, L. Tsali // Experimental Oncology. — 2009. — Т. 31, № 1. — С. 60-61. — Бібліогр.: 18 назв. — англ.

Репозитарії

Digital Library of Periodicals of National Academy of Sciences of Ukraine
id nasplib_isofts_kiev_ua-123456789-135111
record_format dspace
spelling Maur, D.
Panou, C.
Valachis, A.
Kamposioras, K.
Tsali, L.
2018-06-14T15:38:44Z
2018-06-14T15:38:44Z
2009
Tyrosine kinase inhibitors in treatment of fibrous histiocytoma / D. Mauri, C. Panou, A. Valachis, K. Kamposioras, L. Tsali // Experimental Oncology. — 2009. — Т. 31, № 1. — С. 60-61. — Бібліогр.: 18 назв. — англ.
1812-9269
https://nasplib.isofts.kiev.ua/handle/123456789/135111
Aim: To describe potential beneficial effects of tyrosine kinase inhibitor in the treatment of unresectable/metastatic fibrous histiocytoma. Methods: We report a case of advanced stage fibrous histiocytoma with locally recurrent disease plus lung and bone metastatic deposits. Patient was treated with the tyrosine kinase inhibitor sunitinib. Results: Treatment with Sunitinib resulted in disease stabilization in the regional lesion and in good partial response for metastatic foci (reduction in number and size). After 13 months of treatment the patient is doing well with no tumor progression. Conclusions: This case appears to be one of the first documentations of beneficial effect and potential long-term benefit of TKIs in the treatment of fibrous histiocytoma.
en
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
Experimental Oncology
Short communications
Tyrosine kinase inhibitors in treatment of fibrous histiocytoma
Article
published earlier
institution Digital Library of Periodicals of National Academy of Sciences of Ukraine
collection DSpace DC
title Tyrosine kinase inhibitors in treatment of fibrous histiocytoma
spellingShingle Tyrosine kinase inhibitors in treatment of fibrous histiocytoma
Maur, D.
Panou, C.
Valachis, A.
Kamposioras, K.
Tsali, L.
Short communications
title_short Tyrosine kinase inhibitors in treatment of fibrous histiocytoma
title_full Tyrosine kinase inhibitors in treatment of fibrous histiocytoma
title_fullStr Tyrosine kinase inhibitors in treatment of fibrous histiocytoma
title_full_unstemmed Tyrosine kinase inhibitors in treatment of fibrous histiocytoma
title_sort tyrosine kinase inhibitors in treatment of fibrous histiocytoma
author Maur, D.
Panou, C.
Valachis, A.
Kamposioras, K.
Tsali, L.
author_facet Maur, D.
Panou, C.
Valachis, A.
Kamposioras, K.
Tsali, L.
topic Short communications
topic_facet Short communications
publishDate 2009
language English
container_title Experimental Oncology
publisher Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
format Article
description Aim: To describe potential beneficial effects of tyrosine kinase inhibitor in the treatment of unresectable/metastatic fibrous histiocytoma. Methods: We report a case of advanced stage fibrous histiocytoma with locally recurrent disease plus lung and bone metastatic deposits. Patient was treated with the tyrosine kinase inhibitor sunitinib. Results: Treatment with Sunitinib resulted in disease stabilization in the regional lesion and in good partial response for metastatic foci (reduction in number and size). After 13 months of treatment the patient is doing well with no tumor progression. Conclusions: This case appears to be one of the first documentations of beneficial effect and potential long-term benefit of TKIs in the treatment of fibrous histiocytoma.
issn 1812-9269
url https://nasplib.isofts.kiev.ua/handle/123456789/135111
citation_txt Tyrosine kinase inhibitors in treatment of fibrous histiocytoma / D. Mauri, C. Panou, A. Valachis, K. Kamposioras, L. Tsali // Experimental Oncology. — 2009. — Т. 31, № 1. — С. 60-61. — Бібліогр.: 18 назв. — англ.
work_keys_str_mv AT maurd tyrosinekinaseinhibitorsintreatmentoffibroushistiocytoma
AT panouc tyrosinekinaseinhibitorsintreatmentoffibroushistiocytoma
AT valachisa tyrosinekinaseinhibitorsintreatmentoffibroushistiocytoma
AT kamposiorask tyrosinekinaseinhibitorsintreatmentoffibroushistiocytoma
AT tsalil tyrosinekinaseinhibitorsintreatmentoffibroushistiocytoma
first_indexed 2025-11-27T23:58:19Z
last_indexed 2025-11-27T23:58:19Z
_version_ 1850853018708213760